Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ATM | Q13315 | 1/20 | 0.53 |
| ▸ | CYP3A4 | P08684 | 5/20 | 0.47 |
| ▸ | APP | P05067 | 3/20 | 0.45 |
| ▸ | AAK1 | Q2M2I8 | 5/20 | 0.45 |
| ▸ | ACE | P12821 | 1/20 | 0.44 |
| ▸ | CTSS | P25774 | 3/20 | 0.43 |
| ▸ | CTSB | P07858 | 2/20 | 0.43 |
| ▸ | CTSK | P43235 | 2/20 | 0.43 |
| ▸ | CTSL | P07711 | 1/20 | 0.43 |
| ▸ | KLK5 | Q9Y337 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28995695 | 1.00 | ATM (0.53) | ATMCYP3A4APPAAK1ACE | |
| SCHEMBL25807391 | 0.89 | PPARA (0.50) | ATMCYP3A4AAK1CTSSCTSB | |
| SCHEMBL28995644 | 0.89 | PPARA (0.50) | ATMCYP3A4AAK1CTSSCTSB | |
| SCHEMBL30491809 | 0.89 | PPARA (0.50) | ATMCYP3A4AAK1CTSSCTSB | |
| SCHEMBL25295806 | 0.86 | HDAC8 (0.41) | CTSSCTSL | |
| SCHEMBL25256196 | 0.86 | HDAC8 (0.41) | CTSSCTSL | |
| SCHEMBL25811427 | 0.85 | AAK1 (0.47) | ATMAAK1CTSSCTSBCTSK | |
| SCHEMBL28995608 | 0.85 | AAK1 (0.47) | ATMAAK1CTSSCTSBCTSK | |
| SCHEMBL6857744 | 0.84 | ATM (0.53) | ATMCYP3A4APPAAK1ACE | |
| SCHEMBL6857746 | 0.84 | ATM (0.53) | ATMCYP3A4APPAAK1ACE |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12583866-B2 | Pyrido[2,3-b][1,4]oxazines or tetrahydropyrido[2,3-b][1,4]oxazepines as IAP antagonists | BEONE MEDICINES I GMBH (CH) | 2026-03-24 | — | — | US | disclosed |
| US-20230219975-A1 | PYRIDO[2,3-B][1,4]OXAZINES OR TETRAHYDROPYRIDO[2,3-B][1,4]OXAZEPINES AS IAP ANTAGONISTS | BEONE MEDICINES I GMBH (CH) | 2023-07-13 | — | — | US | disclosed |
| US-20230219975-A1 | PYRIDO[2,3-B][1,4]OXAZINES OR TETRAHYDROPYRIDO[2,3-B][1,4]OXAZEPINES AS IAP ANTAGONISTS | BEONE MEDICINES I GMBH (CH) | 2023-07-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12583866-B2 | Pyrido[2,3-b][1,4]oxazines or tetrahydropyrido[2,3-b][1,4]oxazepines as IAP antagonists | BIRC2, BIRC3, BIRC5 | ATM 2668/4885CYP3A4 4330/4885APP 57/4885 |
| US-20230219975-A1 | PYRIDO[2,3-B][1,4]OXAZINES OR TETRAHYDROPYRIDO[2,3-B][1,4]OXAZEPINES AS IAP ANTAGONISTS | BIRC2, BIRC3, API5 | ATM 4002/4885CYP3A4 4647/4885APP 787/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.